Key result
DOACs linked to ~22% lower risk of intracranial hemorrhage vs LMWH in cancer-associated VTE.
Why the study?
The management of cancer-associated thrombosis in patients with brain metastases is challenging due to increased intracranial hemorrhage risk and limited evidence on DOAC safety compared with LMWH in this population.
Do direct oral anticoagulants reduce the risk of intracranial hemorrhage and improve clinical outcomes compared to low-molecular-weight heparin in patients with cancer-associated thrombosis and brain metastases?
Cohort (n=6,414)
Yes
Do direct oral anticoagulants reduce the risk of intracranial hemorrhage and improve clinical outcomes compared to low-molecular-weight heparin in patients with cancer-associated thrombosis and brain metastases?
In patients with brain metastases and cancer-associated thrombosis, DOAC use was associated with significantly lower risks of intracranial hemorrhage and all-cause mortality compared with LMWH, supporting their safety in this high-risk population.
Answers are grounded in this paper and cite their sources.
May support DOAC preference over LMWH for VTE in cancer with brain metastases; extends landmark trials to this subgroup but remains hypothesis-generating.
The management of cancer-associated thrombosis (CAT) in individuals with brain metastases remains a clinical challenge primarily due to the increased risk of intracranial hemorrhage (ICH) (1).The shift
No takes yet. Share an insight, caveat, or question.
Mushtaq et al. (2026) conducted a cohort in Cancer-associated thrombosis in patients with brain metastases (n=6,414). Direct oral anticoagulants (DOACs) vs. Low-molecular-weight heparin (LMWH) was evaluated on Intracranial hemorrhage (ICH) within 12 months (HR 0.78, 95% CI 0.65-0.93, p=<.01). DOAC use was associated with a lower 12-month risk of intracranial hemorrhage compared to LMWH in patients with active cancer, brain metastases, and VTE.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: